IL-16基因-295 T>C多态性与肾透明细胞癌易感性的相关性研究

杜拥军, 殷长军, 朱建, 居小兵, 孟小鑫, 秦超, 王美林, 张正东, 张炜

杜拥军, 殷长军, 朱建, 居小兵, 孟小鑫, 秦超, 王美林, 张正东, 张炜. IL-16基因-295 T>C多态性与肾透明细胞癌易感性的相关性研究[J]. 实用临床医药杂志, 2012, (17): 18-21.
引用本文: 杜拥军, 殷长军, 朱建, 居小兵, 孟小鑫, 秦超, 王美林, 张正东, 张炜. IL-16基因-295 T>C多态性与肾透明细胞癌易感性的相关性研究[J]. 实用临床医药杂志, 2012, (17): 18-21.
DU Yong-jun, YIN Chang-jun, ZHU Jian, JU Xiao-bing, MENG Xiao-xin, QIN Chao, WANG Mei-lin, ZHANG Zheng-dong, ZHANG Wei. Correlation between IL-16 gene-295 T>C polymorphism and risk of renal cell carcinoma[J]. Journal of Clinical Medicine in Practice, 2012, (17): 18-21.
Citation: DU Yong-jun, YIN Chang-jun, ZHU Jian, JU Xiao-bing, MENG Xiao-xin, QIN Chao, WANG Mei-lin, ZHANG Zheng-dong, ZHANG Wei. Correlation between IL-16 gene-295 T>C polymorphism and risk of renal cell carcinoma[J]. Journal of Clinical Medicine in Practice, 2012, (17): 18-21.

IL-16基因-295 T>C多态性与肾透明细胞癌易感性的相关性研究

详细信息
  • 中图分类号: R737.11

Correlation between IL-16 gene-295 T>C polymorphism and risk of renal cell carcinoma

  • 摘要: 目的 研究中国南方汉族人群中白细胞介素-16(IL-16)基因-295 T>C多态性与肾透明细胞癌(CCRCC)易感性的相关性.方法 采用以医院为基础的病例对照研究模式,通过面访填写调查表并采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法检测年龄和性别匹配的中国南方汉族300例患者和300例正常人群的IL-16 gene-295T>C基因型.并采用分层分析进一步探讨与罹患CCRCC相关的可能因素.结果 与TT型携带者相比,CT型(OR=0.78,95%CI=0.55~1.09)或CC型(0.37,0.19~0.73)携带者发生CCRCC的危险性明显降低.分层分析显示年龄、体重指数及饮酒与CCRCC危险性之间无明显关联,携带CT或CC型从不吸烟的女性患者发生CCRCC的危险性明显降低(从不吸烟:0.61,0.41~0.91;女性:0.52,0.30~0.91).结论 IL-16 gene-295T>C多态性可能与我国南方地区汉族人群CCRCC易感性有关,CC型或CT型携带者发生CCRCC的危险性要明显低于TT型携带者.
  • Smith A J, Humphries S E. Cytokine and cytokine receptor gene polymorphisms and their functionality [J]. Cytokine & Growth Factor Reviews, 2009.43.
    Muc-Wierzgon M, Nowakowska-Zajdel E, Kokot T. Genetic disregulation of TNF alpha and TNF alpha type Ⅱ receptors in colon cancer at the Ⅱ and Ⅲ stage of disease [J]. Journal of Biological Regulators and Homeostatic Agents, 2006.10.
    Kai H, Kitadai Y, Kodama M. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma [J]. Anticancer Research, 2005.709.
    Shanmugham L N, Petrarca C, Frydas S. IL-15 an immunoregulatory and anti-cancer cytokine.Recent advances [J]. Journal of Experimental & Clinical Cancer Research, 2006.529.
    Nakayama E E, Wasi C, Ajisawa A. A new polymorphism in the promoter region of the human interleukin-16 (IL-16) gene [J]. Genes and Immunity, 2000.293.
    Liebrich M, Guo L H, Schluesener H J. Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors [J]. Archivum Immunologiae et Therapiae Experimentalis, 2007.41.
    Gao L B, Rao L, Wang Y Y. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer [J]. Carcinogenesis, 2009.295.
    Lipworth L, Tarone R E, McLaughlin J K. The epidemiology of renal cell carcinoma [J]. Journal D Urologie, 2006.2353.
    Setiawan V W, Stram D O, Nomura A.M. Risk factors for renal cell cancer:the multiethnic cohort [J]. American Journal of Epidemiology, 2007.932.
    Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development [J]. Molecular Cancer Research, 2006.221.
    Hussain S P, Harris C C. Inflammation and cancer:an ancient link with novel potentials [J]. International Journal of Cancer, 2007.2373.
    Burkart K M, Barton S J, Holloway J W. Association of asthma with a functional promoter polymorphism in the IL16 gene [J]. Journal of Allergy and Clinical Immunology, 2006.86.
    Gu X J, Cui B, Zhao Z F. Association of the interleukin IL-16 gene polymorphisms with Graves' disease [J]. Clinical Immunology, 2008.298.
计量
  • 文章访问数:  113
  • HTML全文浏览量:  25
  • PDF下载量:  15
  • 被引次数: 0
出版历程
  • 发布日期:  2013-01-15

目录

    /

    返回文章
    返回
    x 关闭 永久关闭